Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB):a multicentre randomised trial by , et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1136/gutjnl-2018-317805
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
ACTIB trial group, Everitt, H. A., Landau, S., O'Reilly, G., Sibelli, A., Stephanie, H., ... Moss-Morris, R. (2019).
Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as
usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut. https://doi.org/10.1136/gutjnl-
2018-317805
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 09. May. 2019
  1Everitt HA, et al. Gut 2019;0:1–11. doi:10.1136/gutjnl-2018-317805
Neurogastroenterology
Original article
Assessing telephone-delivered cognitive–behavioural 
therapy (CBT) and web-delivered CBT versus 
treatment as usual in irritable bowel syndrome 
(ACTIB): a multicentre randomised trial
Hazel anne everitt,  1 Sabine landau,2 gilly O’reilly,1 alice Sibelli,3 Stephanie Hughes,1 
Sula Windgassen,3 rachel Holland,2 Paul little,1 Paul Mccrone,4 Felicity Bishop,5 
Kimberley goldsmith,2 nicholas coleman,6 robert logan,7 trudie chalder,8 
rona Moss-Morris,3 on behalf of actiB trial group
To cite: everitt Ha, landau S, 
O’reilly g, et al. Gut epub 
ahead of print: [please 
include Day Month Year]. 
doi:10.1136/
gutjnl-2018-317805
 ► additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
gutjnl- 2018- 317805).
For numbered affiliations see 
end of article.
Correspondence to
associate Prof Hazel 
anne everitt, Primary care 
and Population Sciences, 
Southampton University, 
Southampton SO16 5St, UK;  
 hae1@ soton. ac. uk
tc and rM-M contributed 
equally.
received 26 October 2018
revised 31 January 2019
accepted 22 February 2019
© author(s) (or their 
employer(s)) 2019. re-use 
permitted under cc BY-nc. no 
commercial re-use. See rights 
and permissions. Published 
by BMJ.
AbsTrACT
Objective to evaluate the clinical effectiveness of two 
modes of cognitive–behavioural therapy (cBt) for iBS 
compared with treatment as usual (taU) in refractory iBS.
Design a three-arm randomised controlled trial 
assessing telephone-delivered cBt (tcBt), web-
based cBt (WcBt) with minimal therapist support, 
and taU. Blinding participants and therapists was not 
possible. chief investigator, assessors and statisticians 
were blinded. Participants were adults with refractory 
iBS (clinically significant symptoms for ≥12 months 
despite first-line therapies), recruited by letter and 
opportunistically from 74 general practices and three 
gastroenterology centres in london and South of 
england between May 2014 to March 2016. co-primary 
outcomes were iBS Symptom Severity Score (iBS-SSS) 
and Work and Social adjustment Scale (WSaS) at 12 
months.
results 558/1452 (38.4%) patients screened for 
eligibility were randomised: 76% female: 91% white: 
mean age 43 years. (391/558) 70.1% completed 12 
months of follow-up. Primary outcomes: compared with 
taU (iBS-SSS 205.6 at 12 months), iBS-SSS was 61.6 
(95% ci 33.8 to 89.5) points lower (p<0.001) in tcBt 
and 35.2 (95% ci 12.6 to 57.8) points lower (p=0.002) 
in WcBt at 12 months. compared with taU (WSaS score 
10.8 at 12 months) WSaS was 3.5 (95% ci 1.9 to 5.1) 
points lower (p<0.001) in tcBt and 3.0 (95% ci 1.3 
to 4.6) points lower (p=0.001) in WcBt. all secondary 
outcomes showed significantly greater improvement 
(p≤0.002) in cBt arms compared with taU. there were 
no serious adverse reactions to treatment.
Conclusion Both cBt interventions were superior to 
taU up to 12 months of follow-up.
Trial registration number iSrctn44427879.
INTrODuCTION
IBS is a common GI disorder affecting 10%–20% of 
the population worldwide and incurring significant 
health costs.1 2 Abdominal pain, bloating and altered 
bowel habit affect quality of life, social functioning 
and time off work.3 Treatment commonly relies on 
a positive diagnosis, reassurance, lifestyle advice 
including diet and drug therapies.3 4 However, many 
patients suffer ongoing symptoms. Psychological 
therapies and particularly face-to-face cognitive–
behavioural therapy (CBT) can reduce symptom 
scores and improve quality of life by targeting 
unhelpful beliefs and coping behaviours5–8 but 
questions remain over optimum modes of delivery, 
adherence to therapy and longer term outcomes. 
The National Institute for Health and Care Excel-
lence (NICE) guidance3 recommends CBT for 
significance of this study
What is already known on this subject?
 ► IBS is common and many people with IBS have 
ongoing symptoms that significantly affect 
quality of life.
 ► Face-to-face cognitive–behavioural therapy 
(CBT) has been shown to be helpful for IBS 
and is recommended in National Institute for 
Health and Care Excellence guidelines but 
there is limited evidence for telephone and 
web-based CBT and uncertainty regarding 
participant’s adherence to CBT and its longer 
term effectiveness.
 ► Currently there is poor availability of CBT for 
people with IBS.
What are the new findings?
 ► This is the first large randomised controlled trial 
in primary and secondary care with long-term 
follow-up to compare low-intensity web-based 
CBT for IBS and higher intensity telephone-
delivered CBT for IBS with treatment as usual.
 ► Both the telephone-delivered and web-
delivered CBT for IBS showed large clinical and 
statistically significant improvements in IBS 
symptoms and impact on life and mood which 
were maintained at 12 months.
 ► Good adherence to treatment and sustained 
improvements in IBS at 12 months can be 
achieved with telephone and web-based CBT 
for IBS.
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patients with refractory IBS symptoms (ie, ongoing symptoms 
after 12 months despite being offered appropriate medications 
and lifestyle advice).
Even assuming there were no questions about the longer term 
effectiveness of CBT, there is very limited access for patients with 
refractory IBS to traditional intensive face-to-face CBT. Within 
resource-constrained health services, telephone-delivered CBT 
(TCBT) and web-based CBT (WCBT) are likely to provide an 
important way of improving access and have the advantage of 
access at a time and place convenient to the participant, at a pace 
that suits individual’s circumstances, without additional travel 
time and costs.
Previous trials show provisional evidence for WCBT (with 
some therapist support) in IBS.9–13 However, to date there are no 
large effectiveness randomised controlled trials (RCT) of WCBT 
for IBS compared with treatment as usual (TAU).
We previously evaluated the efficacy of manualised CBT for 
IBS in primary care delivered by nurses14 and further developed 
it into a self-help manual with guided psychologist support.15 
Subsequently, we developed a tailored, interactive web-based 
version of the manual called Regul8, which was explored in the 
Managing Irritable Bowel Syndrome (MIBS) feasibility trial.9
The aim of the Assessing Cognitive–behavioural Therapy in 
Irritable Bowel syndrome (ACTIB) trial was to compare clinical 
and cost-effectiveness of therapist TCBT and WCBT (Regul8) 
with minimal therapist support with TAU alone16 at reducing IBS 
symptoms and impact.
MeThODs
study design and participants
ACTIB was a parallel three-group, multicentre randomised trial 
with outcomes assessed at 3, 6 and 12 months after randomi-
sation for patients with refractory IBS. Primary endpoint was 
12 months. We recruited UK National Health Service (NHS) 
patients from 74 primary care general practice (GP) surgeries in 
Southern England and London and three secondary care gastro-
enterology outpatient clinics in Southampton and London, May 
2014 to March 2016. Twelve-month data collection completed 
in May 2017.
Trial protocol is published on  BMJOpen. bmj. com.16
Participants were eligible if they fulfilled criteria for refrac-
tory IBS at screening, defined as: fulfilling ROME III criteria 
for IBS17; reported ongoing clinically significant symptoms on 
IBS Symptom Severity Score (IBS-SSS),18 that is, ≧75; had been 
offered first-line therapies (eg, antispasmodics, antidepressants 
or fibre-based medications); and had IBS symptoms ≧12 months. 
Due to the increased risk of bowel cancer, potential participants 
aged >60 years were only included if they had hospital consul-
tant review ≤2 years to confirm symptoms were IBS related and 
exclude serious bowel conditions.
Medical exclusion criteria: unexplained rectal bleeding or 
weight loss, IBD, coeliac disease, peptic ulcer disease, colorectal 
carcinoma. Other exclusions: patients <18 years, unable to 
participate in CBT due to speech or language difficulties, no 
access to internet computer, received CBT in the last 2 years, 
previous access to Regul8 during MIBS trial, currently partici-
pating in another IBS intervention trial.
Primary care patients were identiﬁed by searching GPs’ lists 
for those with an IBS diagnosis and opportunistic recruitment 
of patients with IBS. An invitation letter was sent including a 
patient information sheet and a reply slip. Most secondary care 
recruitment was opportunistic during gastroenterology clinics. 
Adverts were also placed in GP and gastroenterology clinics and 
on NHS websites.
The trial team undertook initial telephone eligibility screening; 
any suggestion of serious pathology, such as unexplained weight 
loss, triggered GP referral for further assessment. Online consent 
preceded screening blood tests: full blood count, C-reactive 
protein and tissue transglutaminase (as per NICE guidelines3). 
If blood tests were within normal limits, participants were able 
to take part.
randomisation and masking
After completing baseline questionnaires, participants were 
randomised to one of the three trial arms. Randomisation was 
at the level of the individual, stratified by recruitment centre, 
with randomly varying block sizes to ensure approximately equal 
group sizes. Randomisation was implemented via an indepen-
dent web-based randomisation service at the UK-CRC registered 
King’s Clinical Trials Unit.
As with any therapy trial, participants, therapists and 
research assistants assisting with therapy arrangements could 
not be masked to treatment allocation. However, trial principal 
investigators and statisticians undertaking outcome analysis 
were masked. Outcomes were completed by participants inde-
pendently of the study team.
Description of CbT interventions and TAu
Two interventions were assessed: therapist TCBT and a low-in-
tensity WCBT—an update of the Regul8 programme developed 
in MIBS9 including eight online sessions, with some therapist 
support.
All arms received TAU, control being TAU alone.
The CBT content of the treatment arms was similar, based 
on an empirical cognitive–behavioural model of IBS,19 consisting 
of education, behavioural and cognitive techniques, aimed 
at improving bowel habits, developing stable healthy eating 
patterns, addressing unhelpful thoughts, managing stress, 
reducing symptom focusing and preventing relapse.
Treatments were standardised by provision of training, super-
vision and manuals for therapists. All therapists were able to be 
significance of this study
how might it impact on clinical practice in the foreseeable 
future?
 ► Currently clinicians have few options to offer people 
with refractory IBS, particularly in primary care. This study 
shows that IBS-specific CBT has the potential to provide 
significant improvement in IBS symptoms, within a National 
Health Service (NHS) setting (NHS therapists delivered the 
interventions).
 ► All therapy was offered remotely so could be made nationally 
available from specialist therapy centres. In addition, 
therapists who currently work in the Improving Access 
to Psychological Therapy services (available throughout 
England) have suitable skills and are well placed to provide 
CBT for IBS.
 ► Potential treatment pathways could be a ‘matched’ approach 
where people with IBS are initially offered the most 
appropriate type of CBT based on initial assessments or a 
‘stepped care’ care approach where all patients are offered 
lower intensity web-based CBT and further therapist input is 
considered for those with particularly troublesome symptoms.
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allocated to participants from all recruitment centres and either 
therapy arm.
Participants randomised to TCBT arm received a detailed 
self-help manual including homework tasks and had six 1-hour 
telephone sessions with a CBT therapist at weeks 1, 2, 3, 5, 7 
and 9. They also received two 1-hour booster sessions at 4 and 
8 months (total 8 hours of therapist support).
WCBT participants received online access to Regul8 and three 
30 min telephone therapy calls at weeks 1, 3 and 5, and two 
30 min booster sessions at 4 and 8 months (2.5 hours of therapist 
support).
TAU was a continuation of current medications and usual GP 
or consultant follow-up with no psychological therapy. All GP 
and secondary care sites received NICE guidance for IBS3 and 
a deskside reminder highlighting protocol guidance and inclu-
sion criteria. All participants received a standard information 
sheet on Lifestyle and Diet in IBS based on NICE guidance.3 
Information was collected on any changes in IBS treatments/
management and numbers of GP and consultant consultations 
were recorded for all trail arms. TAU alone participants were 
given access to WCBT website (but no therapy support) at the 
end of the 12-month follow-up period.
Therapy procedures
Thirteen therapists trained in cognitive behavioural psycho-
therapy (10 [77%] female, mean age 42 years [range 34–52]) 
based at South London and Maudsley NHS Trust provided tele-
phone CBT sessions for both therapy arms. Six therapists were 
clinical psychologists (46%) and seven (54%) were cognitive 
behavioural psychotherapists with a median of 7 years (range 
4–24) experience. All sessions were audio recorded for supervi-
sion and treatment fidelity purposes. Therapists received a ther-
apist manual, 2 days’ training and supervision. TC and RMM 
listened to one therapy tape per therapist per supervision session 
which were conducted in 90 min fortnightly group sessions in 
the first half of the trial, then monthly.
Fidelity was rated by two independent clinical psychologists 
using a fidelity measure specifically adapted for this trial.20 
A random sample of 22/90 WCBT second sessions (24.4%) 
and 23/103 (23.3%) TCBT third sessions were rated. Of 45 
randomly selected recordings, nine were double rated (20%) 
and discussed between raters to ensure consistency. Percentage 
agreement in scale items was 83.95%–99.31%. Double ratings 
showed adequate inter-rater reliability (ie, weighted kappa range 
0.50–0.97) for all items except one, which had a weighted kappa 
of 0.11.
Outcomes
Assessments were undertaken at baseline, and at 3, 6 and 
12 months after randomisation and completed online by partici-
pants (or a paper copy was posted or telephone follow-up under-
taken as described in the protocol).16
Primary outcomes
Two coprimary outcomes at 12 months after randomisation:
IBS-SSS18 measures severity and duration of abdominal pain, 
abdominal distension/tightness, bowel habit and quality of 
life (score 0–500). IBS-SSS is widely used in IBS studies and 
a 50-point within-participant change from baseline regarded 
as clinically significant.18 We used a 35-point between-group 
change as our minimal clinically important difference (MCID) 
assuming some improvement in TAU arm (15 points placebo 
response) as in the MIBS trial.9
The WSAS measures the effect of IBS on ability to work and 
manage at home, participate in social and private leisure activ-
ities and maintain relationships. WSAS is sensitive to change 
in IBS14 15 and has five domains scored 0 (not affected) to 8 
(severely affected), with a total possible score of 40.14
Secondary outcomes
IBS-SSS and WSAS at 3 and 6 months after randomisation, and 
mood, symptom relief and ability to cope with symptoms at 3, 
6 and 12 months.
Subject’s Global Assessment of Relief (SGA)21 assesses IBS 
symptoms relief on a scale of 1–5, from ‘completely relieved’ to 
‘worse’. Scores were dichotomised; 1–3 considered responders 
and 4–5 non-responders.21
Patient Enablement Questionnaire (PEQ)22 assesses partici-
pants’ ability to cope with their illness and life after treatment, 
scored 0–12, higher scores indicating improvement.
SGA and PEQ were not measured at baseline.
Mood was measured by the total distress score23 of the 
Hospital Anxiety and Depression Scale (HADS).24
Adherence to therapy was defined as the number of phone or 
web sessions undertaken: WCBT completing ≥4 website sessions 
and one or more telephone support calls; TCBT completing 
≥4 of the initial telephone CBT sessions.
Participants self-reported adverse events (AE) in follow-up 
questionnaires. Clinicians and therapists reported serious AEs 
on a standard form.
sample size
We powered to detect our MCID of a 35-point difference 
between therapy groups and TAU on IBS-SSS at 12 months. 
Assuming a within-group IBS-SSS SD of 76 (MIBS pilot study9), 
this equates to an effect size of 0.46. To achieve 90% power, at 
2.5% signiﬁcance level (adjusting for two primary outcomes), 
required 119 participants per group. This sample size was 
increased by an inﬂation factor of 1.32, to take account of ther-
apist effects (assuming an intraclass correlation of 0.0225 and a 
workload of 17 participants per therapist), decreased by a deﬂa-
tion factor of 0.84 assuming that baseline values are predictive 
of post-treatment values (correlation 0.4) and further inﬂated 
(factor 1.25) for attrition <20%. The final sample size was 165 
patients per group, or 495 patients in total. For WSAS, this was 
sufﬁcient to detect a difference of 3.7 points or larger, which is 
consistent with previous CBT trials.15
statistical analysis
An intention-to-treat (ITT) approach was used. For each outcome 
and assessment time point (3, 6 or 12 months) we estimated the 
effect of treatment (TCBT or WCBT) compared with TAU to 
assess treatment effectiveness. Significance testing was performed 
at Bonferroni adjusted significance level alpha=0.025 to allow 
for two primary outcomes. Modelling of continuous variables 
relied on normal assumptions for error terms and treatment 
effects were quantified by trial arm differences (and standardised 
differences). To facilitate modelling, the PEQ measure, which 
displayed considerable zero inflation, was reclassified as a binary 
variable, a score of ≥6 considered a ‘responder’. Binary outcome 
variables were analysed within a logistic regression framework 
and treatment effects quantified by ORs.
Formal trial arm comparisons were carried out by multiple 
imputation (MI) using the flexible Multivariate Imputation by 
Chained Equations (MICE) approach.26 Necessary as non-adher-
ence with treatment was found predictive of missing primary 
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outcomes at 12 months in CBT arms. MI can provide estimates 
of trial arm differences valid under such a ‘missing at random 
(MAR)’ process27 (details in online supplementary appendix 1). 
We also empirically assessed whether baseline variables were 
predictive of missing data using logistic regression modelling of 
missingness at 12 months at a liberal 20% test level (see online 
supplementary appendix 2). More severe baseline IBS-SSS and 
index of multiple deprivation (IMD) predicted missingness so 
we included these variables in the imputation to allow for a real-
istic MAR process.
Separate analyses were carried out for each outcome vari-
able and time point. MICE was used with regression or logistic 
regression imputation models for continuous and binary vari-
ables, respectively. Predictive mean matching (10 nearest neigh-
bours) ensured imputed IBS-SSS, WSAS and HADS values lay 
within the observed data range. One hundred imputations were 
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram for Assessing Cognitive–behavioural Therapy in Irritable Bowel syndrome 
(ACTIB) trial. CBT, cognitive–behavioural therapy; GP, general practice; IBS-SS, IBS Symptom Severity Score; MIBS, Managing Irritable Bowel Syndrome; 
TAU, treatment as usual; TCBT, telephone-delivered CBT; WCBT, web-based CBT; WSAS, Work and Social Adjustment Scale. 
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used throughout. MI analysis models included the respective 
outcome variable as the dependent variable, and trial arm (two 
dummy variables indicating the TCBT and WCBT arms), base-
line values of outcome and randomisation stratifier (dummy 
variables for four levels) as explanatory variables. Since both 
TCBT and WCBT involved therapists delivering the interven-
tion possible therapist effects were investigated (see online 
supplementary appendix 3 for procedures to select the model for 
therapist effects). We detected therapist effects in TCBT arm for 
IBS-SSS, SGA responders and PEQ responders at 12 months and 
allowed for therapist-varying random intercepts in TCBT arm 
for these variables. For binary outcomes affected by therapist 
effects estimated ORs were conditioned on the therapist. The 
OR was marginalised across therapists within a stratifier level to 
ensure that all quoted ORs estimate the same effect size measure 
(OR of treatment within a centre). For each outcome variable, 
the MI imputation model included (1) all variables of the anal-
ysis model, (2) measures of outcome variable at other assessment 
time points including baseline, and (3) known predictors of 
missingness (binary adherence variables for each of TCBT and 
Table 1 Demographic and clinical characteristics of the study sample at baseline (n=558)
TCbT
n=186
WCbT
n=185
TAu
n=187
All
n=558
Age (years) Mean (SD) 43.4 (12.5) 43.8 (13.6) 42.0 (13.5) 43.1 (13.2)
Gender Female (%) 139 (74.7) 145 (78.4) 139 (74.3) 423 (75.8)
Ethnicity (%) White 162 (87.1) 171 (92.4) 174 (93.0) 507 (90.9)
Deprivation score34 Mean (SD) 16.7 (12.0) 17.3 (12.3) 17.2 (11.8) 17.1 (12.0)
Seen a GI consultant for IBS Count (%) 20 (10.7) 15 (8.1) 22 (11.8) 57 (10.2)
Years of symptoms before diagnosis n/Median 186/3.3 185/3.0 187/3.0 558/3.0
Range 0.0–47.0 0.0–40.0 0.0–40.0 0.0-47.0
Duration of IBS (years) n/Median 185/6.5 185/8.6 187/6.3 557/7.4
Range 1.0–65.0 0.7–45.4 0.3–49.9 0.3–64.6
HADS anxiety score Mean (SD) 10.6 (4.3) 11.1 (4.3) 10.5 (4.0) 10.7 (4.2)
Case*/n (%) 89/186 (47.9) 98/185 (53.0) 96/187 (51.3) 283/558 (50.7)
HADS depression score Mean (SD) 5.5 (3.6) 5.9 (3.8) 5.6 (3.5) 5.7 (3.7)
Case*/n (%) 47/186 (25.3) 60/185 (32.4) 50/187 (26.7) 157/558 (28.1)
IBS subtype
IBS diarrhoea n (%) 60 (32.3) 60 (32.4) 58 (31.0) 178 (31.9)
IBS constipation n (%) 26 (14.0) 23 (12.4) 27 (14.5) 76 (13.6)
IBS alternating† n (%) 93 (50.3) 98 (53.0) 96 (51.3) 287 (51.5)
IBS unclassified n (%) 6 (3.2) 4 (2.2) 6 (3.2) 16 (2.9)
*HADS case of anxiety defined as scoring ≧10/21 and depression as scoring ≧7/21 on subscale.
†IBS-A or alternating is also referred to as IBS-M or mixed.
HADS, Hospital Anxiety and Depression Scale; IMD, index of multiple deprivation; TAU, treatment as usual; TCBT, telephone-delivered CBT; WCBT, web-based CBT.
Figure 2 IBS-SSS means by trial arm. IBS-SSS, IBS Symptom Severity Score; TAU, treatment as usual; TCBT, telephone-delivered CBT; WCBT, web-
based CBT. 
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WCBT, IBS-SSS and IMD). For analysis models that contained 
(random) therapist effects, (4) fixed effects for therapists in 
TCBT arm were also added. Relevant model assumptions were 
checked, including normality and homogeneity assumptions, 
and found satisfactory.
Results of complete case analyses are provided in online 
supplementary appendix 4. Four sensitivity analyses were 
conducted. Their purpose and technical details are provided in 
online supplementary appendix 5. All analyses were carried out 
in Stata version14.2.
Patient and public involvement
Patient and public involvement (PPI) representatives participated in 
the trial management group and trial steering committee and were 
included in all phases of trial design, including planning recruitment 
and recruitment materials. They had participated in MIBS9 and thus 
were able to provide first-hand insight into intervention burden and 
time required to participate in the research. CBT interventions were 
developed and updated with PPI input.9 28
Trial results will be emailed to all participants and published 
on the trial website.
resulTs
Five hundred and fifty-eight (38.4%) of 1452 patients screened 
for eligibility were recruited, May 2014 to March 2016: 186 
were randomised to TCBT, 185 to WCBT and 187 to TAU.
Figure 1, Consolidated Standards of Reporting Trials, 
describes participants’ journey. The most common ineligibility 
reasons were: failure to have refractory IBS or not being offered 
first-line therapies.
Over-recruitment relative to the original sample size calcula-
tion of 495 was undertaken (with ethical approval, within orig-
inal recruitment time frame) to compensate for a lower follow-up 
rate than originally estimated (≈80%).9 Follow-up rates were: 
76.5% (427/558) at 3 months, 72.9% (407/558) at 6 months 
and 70.3% (392/558) at 12 months. One-year follow-up was 
completed in April 2017.
Adherence
For TCBT arm, 84.4% of participants completed at least four 
phone calls. For WCBT arm, 88.1% of participants completed 
at least one phone call, and 69.2% completed four web sessions.
Fidelity
Mean fidelity ratings were high and similar for TCBT and WCBT. 
Therapeutic alliance: mean score 93.2 (range 71.4–100.0) (SD 
10.4) for TCBT and 94.4 (range 57.1–100.0) (SD 10.3) for WCBT. 
CBT Skills mean score 78.5 (range 46.4–92.9) (SD 13.1) for TCBT 
and 82.8 (range 54.3–97.1) (SD 12.1) for WCBT. Therapy adher-
ence mean score 90.1 (range 71.4–100.0) (SD 10.0) for TCBT and 
89.4 (range 42.9–100.0) (SD 15.1) for WCBT.
baseline characteristics
Table 1 shows participants’ baseline characteristics. 75.8% were 
female, mean age was 43.1 years (SD=13.2) and median duration 
since diagnosis was 7.4 years (range 0.3–64.6). 10.2% had seen a GI 
consultant regarding their IBS. Mean IBS-SSS was 265 (SD=95.5) 
indicating moderately severe IBS and baseline mean WSAS score 
was 12.5 suggesting significant, but not severe functional impair-
ment. Mean baseline HADS anxiety score was 10.7 (SD=4.2) with 
50.7% (283/588) scoring ≧10/21 and mean HADS depression 
score was 5.7 (SD=3.7) with 28.2% (157/558) scoring ≧7/21.29 All 
baseline characteristics were well balanced between groups.
Primary outcome measures
Figures 2 and 3 illustrate primary outcome measure change over 
time by trial arm. Table 2 summarises primary and secondary 
outcomes and table 3 provides formal trial arm comparisons. 
Compared with TAU (IBS-SSS of 205.6 at 12 months), IBS-SSS 
was 61.6 (95% CI 33.8 to 89.5) points lower (p<0.001) in 
TCBT and 35.2 (95% CI 12.6 to 57.8) points lower (p=0.002) 
in WCBT at 12 months. Ninety-nine of 136 (72.8%) participants 
had a clinically significant change in IBS-SSS (≧50 points) from 
Figure 3 WSAS means by trial arm. TAU, treatment as usual; TCBT, telephone-delivered CBT; WCBT, web-based CBT; WSAS, Work and Social 
Adjustment Scale. 
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baseline to 12 months in TCBT compared with 82/124 (66.1%) 
in WCBT and 58/131 (44.3%) in TAU.
WSAS score in TAU was 10.8 at 12 months and 3.5 (95% CI 
1.9 to 5.1) points lower (p<0.001) in TCBT and 3.0 (95% CI 
1.3 to 4.6) points lower (p=0.001) in WCBT.
secondary outcome measures
Secondary outcome measures also showed significant improve-
ment in both therapy arms compared with TAU at all assessment 
time points (table 3). For subjects’ global improvement of symp-
toms (SGA) 41.7% were responders in TAU. Odds of being an 
SGA responder were raised by a factor of 6.1 for TCBT (95% CI 
2.5 to 15.0; p<0.001) and by a factor of 3.6 for TCBT (95% CI 
2.0 to 6.3; p<0.001). For patient enablement (PEQ) 23.5% were 
responders in TAU. Odds of being a PEQ responder were raised 
by a factor of 9.3 for TCBT (95% CI 4.5 to 19.3; p<0.001) and 
by a factor of 3.5 for WCBT (95% CI 2.0 to 5.9; p<0.001). For 
HADS at 12 months compared with TAU (mean HADS score 15.0 
[SD 7.2]), scores were an estimated 2.8 (95% CI 1.5 to 4.1) points 
lower (p<0.001) in the TCBT and 2.3 (95% CI 1.0 to 3.7) points 
lower (p=0.001) in the WCBT at 12 months.
Sensitivity analyses demonstrated that: findings were robust 
regarding timing of refractory IBS eligibility assessment or 
timing of outcome recording; using a different threshold to 
define PEQ responders did not affect substantive conclusions; 
Table 3 Formal comparisons between therapy arms and TAU*
TCbT versus TAu WCbT versus TAu
estimated 
difference 95% CI
Test (df)
P value
standardised 
difference†
estimated 
difference 95% CI
Test (df)
P value
standardised 
difference†
IBS-SSS
  3 months −69.2 −88.7 to −49.7 t=−7.0 (367)
<0.001
0.73 −53.0 −74.9 to −31.1 t=−4.7 (237)
<0.001
0.56
  6 months −58.3 −80.3 to −36.3 t=−5.2 (295)
<0.001
0.61 −35.7 −58.5 to −12.9 t=−3.1 (257)
0.002
0.37
  12 months‡ −61.6 −89.5 to −33.8 t=−4.3 (1581)
<0.001
0.65 −35.2 −57.8 to −12.6 t=− 3.1 (275)
0.002
0.37
WSAS
  3 months −3.4 −4.8 to −2.0 t=−4.8 (355)
<0.001
0.40 −3.0 −4.4 to −1.5 t=−3.9 (288)
<0.001
0.35
  6 months −2.7 −4.2 to −1.2 t=−3.6 (280)
<0.001
0.32 −2.5 −4.0 to −1.0 t=−3.3 (257)
0.001
0.30
  12 months −3.5 −5.1 to −1.9 t=−4.2 (268)
<0.001
0.41 −3.0 −4.6 to −1.3 t=−3.5 (258)
0.001
0.35
HADS
  3 months −2.1 −3.2 to −0.9 t=−3.6 (306)
<0.001
0.30 −2.5 −3.7 to −1.3 t=−4.0 (261)
<0.001
0.36
  6 months −2.2 −3.5 to −0.8 t=−3.2 (227)
0.002
0.32 −2.9 −4.2 to −1.6 t=−4.2 (230)
<0.001
0.42
  12 months −2.8 −4.1 to −1.5 t=−4.3 (248)
<0.001
0.41 −2.3 −3.7 to −1.0 t=−3.4 (217)
0.001
0.34
estimated 
Or 95% CI
Test (df)
P value estimated Or 95% CI
Test (df)
P value
PEQ responders
  3 months 13.3 6.9 to 25.8 t=7.7 (1347)
<0.001
6.6 3.3 to 13.2 t=5.4 (918)
<0.001
  6 months 11.6 6.4 to 20.9 t=8.1 (1134)
<0.001
4.8 2.7 to 8.7 t=5.2 (889)
<0·001
  12 months‡ 9.3§ 4.5 to 19.3 t=6.0 (2369)
<0.001
3.5 2.0 to 5.9 t=4.5 (1079)
<0.001
SGA responders
  3 months 10.2 5.8 to 18.1 t=8.1 (1289)
<0.001
6.4 3.6 to 11.3 t=6.3 (824)
<0.001
  6 months 6.2 3.7 to 10.4 t=6.9 (1637)
<0.001
5.0 2.8 to 8.8 t=5.6 (630)
<0.001
  12 months‡ 6.1¶ 2.5 to 15.0 t=3.9 (2957)
<0.001
3.6 2.0 to 6.3 t=4.4 (600)
<0.001
*All inferences were derived by multiple imputation as described in the Methods section. Each model used 100 imputations.
†Differences were standardised by dividing by baseline SD for IBS-SS (95.5), WSAS (8.8) and HADS (6.9), respectively.
‡The 12-month model included therapist effects in the TCBT arm.
§The reported TCBT effect is a conditional effect (conditioned on therapist). The corresponding marginal ORs within site are 9.0 (Southampton GP Practices), 9.2 (Southampton 
Secondary Care), 9.3 (London GP Practices) and 9.3 (London Secondary Care).
¶The reported TCBT effect is a conditional effect (conditioned on therapist). The corresponding marginal ORs within site are 5.8 (Southampton GP Practices), 6.0 (Southampton 
Secondary Care), 5.9 (London GP Practices) and 5.9 (London Secondary Care).
HADS, Hospital Anxiety and Depression Scale; IBS-SSS, IBS Symptom Severity Score; PEQ, Patient Enablement Questionnaire; SGA, Subject’s Global Assessment of Relief; TAU, 
treatment as usual; TCBT, telephone-delivered CBT; WCBT, web-based CBT; WSAS, Work and Social Adjustment Scale.
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Complier Average Causal Effect, using predefined adherence 
criteria, revealed that efficacies for those who comply with CBT 
interventions were higher than the values suggested by ITT anal-
yses (online supplementary appendix 5).
There were very few serious and no intervention-related 
AEs; 77 were recorded in TCBT, 61 in WCBT and 55 in TAU. 
These were varied and split between body system codes. Thir-
ty-five were recorded as GI AE (14 in TCBT, 10 in WCBT and 
11 in TAU) and 45 were psychologically recorded as AE (18 
in TCBT, 17 in WCBT and 10 in TAU). One would expect to 
see increased rates of reported AE in CBT arms, and particu-
larly in TCBT as therapists completed AE forms for any AE 
mentioned during therapy sessions.
DIsCussION
Compared with TAU, both TCBT and WCBT intervention 
arms showed clinically important and/or statistically significant 
improvements in all primary and secondary outcomes at all time 
points sustained at 12 months. These results indicate that both 
TCBT and WCBT are effective treatments for refractory moder-
ately severe IBS compared with TAU.
Trial strengths include a well-powered rigorously conducted 
RCT with broad inclusion and long-term follow-up. The 
IBS-specific CBT was based on an explicit theoretical model19 
which informed detailed patient and therapy manuals and the 
WCBT (Regul8). Therapists were experienced in delivering CBT 
and trained and supervised to deliver IBS-specific CBT. Trial 
interventions had good treatment fidelity and were delivered by 
NHS therapists in an NHS setting.
In terms of limitations, trial participants may not be represen-
tative of all patients with IBS. To address this, we used broad 
inclusive recruitment methods from primary and secondary care. 
However, people unwilling to consider undertaking CBT for IBS 
are unlikely to have participated. Encouragingly, age and gender 
were very similar between those invited and those randomised 
suggesting, on basic demographics, the sample was broadly 
representative though ethnic diversity was limited. Follow-up 
was below the 80% in the original sample size calculation despite 
extensive efforts, with rates of 76.5% and 70.3% at 3 and 
12 months. To mitigate this and maintain power, more partici-
pants were recruited (558 compared with 495). Additionally, an 
ITT analysis with MI ensured valid results despite missing data.
Previous research has shown face-to-face and TCBT to be 
beneficial for IBS6 14 15 particularly immediately after therapy. 
However, a Cochrane review6 highlighted uncertainty in longer 
term. Other large published trials of CBT for IBS report 6-month 
follow-up.13 30 ACTIB found large beneficial results maintained 
at 12 months, possibly related to the IBS-specific CBT, therapist 
training, comprehensive participant CBT manual and booster 
sessions. Significant results were found despite large positive 
improvements in the TAU group.
A recently published three-arm RCT (n=436) compared face-
to-face CBT for IBS with home-based CBT (minimal contact 
cognitive behavioural therapy (MC-CBT)) using self-study mate-
rials, and IBS education alone (EDU).30 They reported improve-
ment at 2 weeks in both CBT arms compared with EDU, and 
on gastroenterologist (but not patient) ratings at 6 months on 
the clinical global impressions improvement scale, suggesting 
promise for low-intensity CBT for IBS. However, they only 
recruited participants from tertiary centres, reported 6-month 
follow-up and failed to show significantly greater improvements 
for CBT on IBS-SSS at any time point. ACTIB recruited more 
broadly, found large improvements in IBS-SSS and global symp-
toms (SGA) at all time points with 2.5 hours of telephone therapy 
for WCBT compared with 4 hours of face-to-face therapy in 
MC-CBT.
Limited adherence is a concern with CBT for IBS with face-
to-face6 and web-based therapy.13 31 The Kennedy trial14 which 
assessed nurse-delivered CBT found fewer than half partici-
pants completed therapy, 41% declining or dropping out due 
to time issues such as work and child care commitments. ACTIB 
had good adherence (84% TCBT, 70% WCBT), possibly due 
to telephone rather than face-to-face delivered therapy and 
flexibility regarding appointment times. Lower adherence 
rates with WCBT are consistent with research in other condi-
tions.32 Although adherence was lower in WCBT than TCBT, 
the primary outcome measure changes were clinically significant 
and sustained at 12 months. Effects were even larger when only 
adherent patients were considered.
Most other minimal contact IBS interventions have relied on 
self-referral and thus have likely recruitment biases10 13 whereas all 
patients with IBS in participating centres were invited to ACTIB, 
suggesting Regul8 with minimal contact is largely acceptable.
The ACTIB findings build on results from other trials9–11 13 33 
showing promise for WCBT for IBS, with significant improve-
ments in IBS symptoms maintained at 12 months with minimal 
therapist input (2.5 hours). However, these were skilled CBT 
therapists, so it may not apply to low-intensity interventions 
with non-CBT-trained health professionals.
Currently, clinicians have few options to offer people with refrac-
tory IBS, particularly in primary care. This study shows IBS-spe-
cific TCBT and WCBT can provide significant improvement in IBS 
symptoms, within an NHS setting (NHS therapists delivered the 
interventions). All therapy was offered remotely so could be made 
nationally available from specialist therapy centres. Therapists who 
currently work in the ‘Improving access to psychological therapy’ 
services (available throughout England) have suitable skills and are 
well placed to provide CBT for IBS. Potential treatment pathways 
include a ‘matched’ approach where people are offered TCBT 
or WCBT based on initial assessments or a ‘stepped care’ care 
approach where all patients are offered lower intensity WCBT and 
therapist input is considered as required.
We are undertaking a process evaluation to explore which form 
of CBT is most appropriate for which patients with IBS. Future 
publications are planned on the cost-eﬀectiveness, a nested qual-
itative study of participant’s perceptions, investigation of moder-
ators and mediators of CBT effects and longer term follow-up. 
Further research is needed to assess whether TCBT and WCBT 
can be widely disseminated in non-trial clinical settings.
CONClusION
This large rigorous trial of CBT for IBS found that both CBT 
arms were superior to TAU at 12 months. This trial reinforces 
NICE guidance,3 which currently relies on a limited evidence 
base of mostly face-to-face CBT, that patients with refractory 
IBS can benefit from CBT for IBS and that telephone-deliv-
ered (TCBT) or web-delivered (WCBT) can provide sustained 
improvements.
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